Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (RGEN) drives innovation in bioprocessing technologies critical for biologics manufacturing, serving pharmaceutical companies and CDMOs worldwide. This page provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access comprehensive coverage of Repligen's strategic initiatives, including financial results, product innovations, and partnership announcements. Our curated news collection enables stakeholders to track the company's impact on biomanufacturing efficiency and therapeutic development pipelines.
Explore updates across key operational areas: quarterly earnings disclosures, regulatory milestones for filtration systems and chromatography products, R&D advancements in process analytics, and global expansion efforts. Content is rigorously verified to ensure alignment with market-moving developments.
Bookmark this page for streamlined access to Repligen's evolving market position. Regularly updated coverage supports informed analysis of the company's role in advancing next-generation drug manufacturing technologies.
Repligen (NASDAQ:RGEN) will attend several investor conferences in May, including RBC Capital Markets' Global Healthcare Conference in New York, Craig-Hallum's Institutional Investor Conference in Minneapolis, and Leerink Partners' Healthcare Crossroads Conference in Austin. Jason K. Garland, Chief Financial Officer, will participate in analyst-led discussions and one-on-one meetings with investors at each event. Live webcasts of the RBC and Leerink presentations will be accessible via Repligen's Investor Relations website.
Repligen reported first quarter revenue of $151 million, a 16% increase in new modalities revenue, and a 12% increase in Filtration (non-COVID) revenue year-over-year. The company achieved a nine-month book-to-bill ratio of 1.03. Financial performance in Q1 2024 saw a decline in reported revenue and gross profit compared to Q1 2023, primarily due to COVID-related revenue absence and a decline in Proteins revenue. Adjusted figures showed a decrease in income from operations and net income. Cash, cash equivalents, and short-term investments at the end of Q1 2024 were $780.6 million. Repligen reiterated its financial guidance for full year 2024, expecting orders to pick up in the second half of the year. The company's adjusted financial guidance for FY 2024 remains unchanged, with total reported revenue expected to be in the range of $620M - $650M.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
